FATE

0.95045.90%
MH

Martin Hosking

Head of Research

Dr. Martin Hosking serves as Head of Research of Fate Therapeutics, Inc. from 2026. Dr. Hosking is responsible for overseeing and advancing the development of iPSC-derived immune cell therapies to clinical evaluation for patients with cancer and autoimmune diseases. With more than two decades of research and leadership experience spread across academia and biotechnology, Dr. Hosking has co-authored numerous studies and patents related to the generation, regulation and maintenance of immune cell responses to cancer and viruses. Dr. Hosking has B.S. in Molecular Biology, Biochemistry, Biological Sciences from University of California, Irvine. Dr. Hosking has Ph.D. in Molecular Biology, Biochemistry, Biological Sciences from University of California, Irvine.

公司职务